Current Status of Tissue Engineering Heart Valve.
The development of surgically implantable heart valve prostheses has contributed to improved outcomes in patients with cardiovascular disease. However, there are drawbacks, such as risk of infection and lack of growth potential. Tissue-engineered heart valve (TEHV) holds great promise to address these drawbacks as the ideal TEHV is easily implanted, biocompatible, non-thrombogenic, durable, degradable, and ultimately remodels into native-like tissue. In general, three main components used in creating a tissue-engineered construct are (1) a scaffold material, (2) a cell type for seeding the scaffold, and (3) a subsequent remodeling process driven by cell accumulation and proliferation, and/or biochemical and mechanical signaling. Despite rapid progress in the field over the past decade, TEHVs have not been translated into clinical applications successfully. To successfully utilize TEHVs clinically, further elucidation of the mechanisms for TEHV remodeling and further translational research outcome evaluations will be required. Tissue engineering is a major breakthrough in cardiovascular medicine that holds amazing promise for the future of reconstructive surgical procedures. In this article, we review the history of regenerative medicine, advances in the field, and state-of-the-art in valvular tissue engineering.
Department of Cardiothoracic Surgery, Nationwide Children's Hospital, Columbus, OH, USA toshiharu.shinoka@nationwidechildrens.org.
Toshiharu
T
Shinoka
Department of Cardiothoracic Surgery, Nationwide Children's Hospital, Columbus, OH, USA.
Hideki
H
Miyachi
D000818:Animals; D006349:Heart Valve Diseases / Q000601:surgery*; D006350:Heart Valve Prosthesis; D006351:Heart Valves / Q000601:surgery*; D006801:Humans; D023822:Tissue Engineering / Q000379:methods*
cell seeding; congenital heart disease; iPS cell; pediatric cardiac surgery; scaffolds; stem cell; tissue engineering; tissue-engineered heart valve